Investing
Argus Makes Model Portfolio Changes (NUE, HCP, MDT, AMGN, HUM, ADI, JNPR, ELX, IPG)
Published:
Argus offers what is truly considered to be independent investment research. This gives the firm the lack of any or most of the traditional conflicts of interest that can be the case as far as Wall St. sell-side upgrades and downgrades are concerned. That is perhaps one of the top reasons why we give them high marks when their team of CFAs and analysts come up with research ideas.
In the Equity Income model portfolio, the firm says to add to positions in Nucor Corp. (NYSE: NUE) and in HCP Inc. (NYSE: HCP).
In the Growth & Income model portfolio, Argus said to buy Medtronic Inc. (NYSE: MDT) and Amgen Inc. (NASDAQ: AMGN). It also said to sell its positions in Humana Inc. (NYSE: HUM) and in Analog Devices Inc. (NASDAQ: ADI).
The final model portfolio changes came in the Mid-Cap Growth portfolio. Argus recommended buying a full position in Juniper Networks Inc. (NYSE: JNPR) at $17.82 and selling the full position in Emulex Corp. (NYSE: ELX), as well as selling out the position in Interpublic Group of Companies Inc. (NYSE: IPG).
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
